Hostname: page-component-77f85d65b8-pztms Total loading time: 0 Render date: 2026-03-26T19:39:03.822Z Has data issue: false hasContentIssue false

Folding of copper proteins: role of the metal?

Published online by Cambridge University Press:  07 March 2018

Candan Ariöz
Affiliation:
Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden
Pernilla Wittung-Stafshede*
Affiliation:
Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden
*
*Author for correspondence: Pernilla Wittung-Stafshede, Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden. Email: Pernilla.wittung@chalmers.se
Rights & Permissions [Opens in a new window]

Abstract

Copper is a redox–active transition metal ion required for the function of many essential human proteins. For biosynthesis of proteins coordinating copper, the metal may bind before, during or after folding of the polypeptide. If the metal binds to unfolded or partially folded structures of the protein, such coordination may modulate the folding reaction. The molecular understanding of how copper is incorporated into proteins requires descriptions of chemical, thermodynamic, kinetic and structural parameters involved in the formation of protein–metal complexes. Because free copper ions are toxic, living systems have elaborate copper-transport systems that include particular proteins that facilitate efficient and specific delivery of copper ions to target proteins. Therefore, these pathways become an integral part of copper protein folding in vivo. This review summarizes biophysical-molecular in vitro work assessing the role of copper in folding and stability of copper-binding proteins as well as protein–protein copper exchange reactions between human copper transport proteins. We also describe some recent findings about the participation of copper ions and copper proteins in protein misfolding and aggregation reactions in vitro.

Information

Type
Review
Copyright
Copyright © Cambridge University Press 2018 
Figure 0

Fig. 1. Paths for folding and metal binding of copper proteins. Illustration of putative folding/binding mechanisms for copper proteins (adapted from Gomes, C. M. and P. Wittung-Stafshede (2010) Metal ion, Protein Folding, and Conformational States: An Introduction in Protein Folding and Metal Ions: Mechanisms, Biology and Disease (2010). Ed(s): C. M. Gomes and P. Wittung-Stafshede Florida, CRC Press: 3–11). The protein may be released from the ribosome followed by folding and the last step be metal insertion, or the polypeptide be released followed by metal insertion and subsequently, folding. It is also possible, that the metal is inserted at the ribosome, followed by release and folding. Intermediate mechanisms are also possible.

Figure 1

Table 1. Basic properties (name, organism, fold, function, Cu site and size) of the proteins discussed with respect to folding and stability in Section 2

Figure 2

Fig. 2. Analysis of protein folding and stability in vitro. (a) Visible absorption of metal-ligand bonds reveals information on cofactor coordination (here folded, red and unfolded, blue, Cu-loaded azurin). (b) Fluorescence from aromatic residues reports on local environment, tertiary interactions and solvent exposure (here folded, red and unfolded, blue, apo-azurin). (c) Far-UV CD reports on the secondary structure content of proteins (here folded, red, and unfolded, blue, Cu-azurin). (d) Energy diagram for a protein folding with a two-state mechanism (folded and unfolded states are separated by a high energy barrier called the transition state). (e) Two-state equilibrium unfolding curve (fraction folded on y axis; chemical denaturant on x-axis). (f) A semi-logarithmic so-called Chevron plot of observed rate constants as a function of chemical denaturant for a two-state kinetic folding/unfolding reaction (here, data for apo-azurin). Reproduced with permission from (Palm-Espling, Niemiec et al.2012).

Figure 3

Fig. 3. Analysis of folding transition state structure. (a) Scheme of stopped-flow mixing set up. Protein unfolded in high denaturant is mixed with buffer to reach a lower denaturant concentration such that the conditions now favor folding. Structural change is probed by spectroscopic changes as a function of time. (b) Energy diagram for a protein folding with a two-state mechanism (folded, unfolded and transition states indicated as U, F and TS) showing changes in transition state and folded state energies for the extreme ϕ-values of 1 (blue) and 0 (red). For a ϕ-value of 1 (blue), the energetic change of the transition state (i.e. effects on folding rates; ΔΔGTS−U) matches that of the folded state (i.e. effect on folded state stability; ΔΔGF−U), implying that the mutated residue makes native-like contacts already in the folding transition state. For a ϕ-value of 0 (red), there is no effect on folding rate constants (i.e. ΔΔGTS−U = 0) as the residue mutated only make native-like contacts late in the folding reaction or only in the folded state. ϕ-values may also be fractional values between 0 and 1, and may then imply partial structure formed in the TS.

Figure 4

Fig. 4. Biophysical methods to probe copper protein stability, metal-protein interactions and protein/metal site properties. (a) Example of typical DSC trace showing protein unfolding. (b) Example of ITC data for titration of ligand to protein. (c) HSQC NMR spectra of 15N-labeled human Atox1 (apo, black; Cu(I)-loaded, red). (d) Typical EPR spectrum of blue copper protein (here, spinach plastocyanin (Xue et al.1998) at 140 K).

Figure 5

Fig. 5. Ribbon illustrations of Cu proteins discussed with respect to in vitro folding. Cu ions are shown as blue spheres. Also shown are enlargements of Cu sites with involved coordination residues noted (for C and D, the T1, T2 and T3 Cu sites are similar and here shown only for Fet3p). (a) P. aeruginosa azurin, 3FSA, (b) human Atox1, 1TL4, (c) human ceruloplasmin, 4ENZ and (d). yeast Fet3p, 1ZPU.

Figure 6

Fig. 6. Possible folding paths and energy landscapes for azurin. (a) Two extreme paths to folded, Cu-loaded azurin from unfolded protein and free Cu(II) ions. Path 1 (green), Cu binding before protein folding; Path 2 (red), protein folding before Cu binding (F, folded, U, unfolded). (b) Illustration showing an activation barrier that unifies the kinetic behaviors determined experimentally for apo- and zinc-forms of azurin. A small pointed feature in apo-azurin's free-energy profile (dashed curve) may account for a fixed transition state (TSapo). The presence of zinc suppressed this high-energy feature and reveals the underlying broad activation barrier (solid curve). This flat and broad barrier results in a moving transition state (TSZn) for zinc-substituted azurin as a function of denaturant concentration. (Figure B adapted from (Wilson & Wittung-Stafshede, 2005a, b)).

Figure 7

Fig. 7. Chemically-induced unfolding of holo- and apo-CP. Folded holo-CP containing six bound coppers (circles), F6Cu, unfolds partially in a reversible transition with a midpoint at ~4·3 M urea to an intermediate form (I4Cu) in which it has lost two Cu and about half of the oxidase activity. The catalytic cluster and therefore domains 1 and 6 are likely intact in the intermediate. Further increase in urea concentration leads to full CP unfolding accompanied by loss of all coppers, UApo. Analogously, apo-CP, FApo, undergoes a reversible urea-induced transition with a midpoint at ~3·7 M to an intermediate state (IApo), followed by an irreversible transition to UApo upon addition of more urea. The final unfolded state of apo-CP is similar to that obtained when starting from holo-CP. Upon attempts to refold, UApo undergoes a reversible off-pathway transition to a molten globule-like state, termed MGApo. Double-headed arrows indicate reversibility; single-headed arrows depict transitions that only go in one direction. Figure adapted from (Sedlak & Wittung-Stafshede, 2007).

Figure 8

Fig. 8. Cu transport paths in the human cytoplasm. Uptake of Cu is mediated by Ctr1. Then Cu is transported by Atox1 to ATP7A/B in the Golgi network for loading of Cu-dependent enzymes in the secretory pathway. CCS transports Cu to SOD1 in the cytoplasm. Cox17 (together with Cox11, Sco1 etc.) moves Cu to the mitochondria for loading of COX.

Figure 9

Fig. 9. Proteins mediating Cu transport via the secretory path. (a) Schematic structure of Cu uptake protein Ctr1. (b) Schematic structure of the P1B-type ATPase ATP7B in the Golgi membrane. For A- and N-domains, 2KIJ and 2ARF were used. For the model of the six MBDs, PBD files 2N7Y, 2LQB, 2ROP, and 2EW9 were combined. TGE and SEHPL motifs are labeled in green and magenta, respectively. (c) General Post-Albers catalytic mechanism for P-type ATPases involving ATP hydrolysis and high-Cu affinity, E1, and low-Cu affinity, E2, states.

Figure 10

Fig. 10. Cu-dependent hetero-complex of Atox1-MBD4. (a) Structural model of Atox1-MBD4 complex highlighting Cu-binding Cys residues in red. (b). Proposed two-step mechanism for Cu (blue) transfer from Atox1 (gold/yellow) to MBD4 (silver/grey) along with thermodynamic (ΔH and TΔS) values for step 1 and step 2 (shown for direction to the right) determined for the Atox1-MBD4 pair (Niemiec et al.2012).

Figure 11

Fig. 11. Structures of proteins mediating Cu transport to SOD1 and COX. (a) Heterodimer between yeast SOD1 (silver) and all three domains of yeast CCS (yellow, domain 1; gold, domain 2; red, domain 3) (1JK9), (b) Bovine heart COX (1V55). (c) Sinorhizobium meliloti Cox11 (1SP0) (D) Human Cox17 (2RNB), (E) Human SCO1 (2GT6). In all, Cu ions are represented in cyan and Zn in magenta.

Figure 12

Fig. 12. Cu binding to Parkinson's disease protein αS. Cu(II)- and Cu(I)-binding sites in the 140-residue αS polypeptide are schematically shown (top), along with helical form of αS found when bound to lipid vesicles (1XQ8) (bottom).

Figure 13

Fig. 13. Cu binding to the amyloid-β peptide, Aβ. Top. Cu(II) binding sites and domain arrangement of full-length APP (GFLD, growth factor-like domain; CuBD, Cu-binding domain; CAPPD, central APP domain; AICD, APP intracellular domain; RERMS, sequence segment which participates in dimerization; linker contains the Aβ peptide). Bottom. Sequence of Aβ peptide with secretase cleavage sites indicated, as well as possible Cu binding residues highlighted in red (Mathys & White, 2017).

Figure 14

Fig. 14. Cu binding to the prion protein, PrP.Top. The PrP protein (residues 1–254) is schematically shown indicating the octa-peptide repeat (OPR) domain (with amino acid sequences) and the Cu binding sites (arrows). Also shown are positions for SP, signal peptide, HS, hydrophobic segment, α-helices (H1-H3), β-strands, a disulfide connecting H2 and H3, the C-terminal GPI anchor; and, protruding ovals indicate N-linked glycans (Brown, 2001; Giachin et al.2015). Hot-spot areas for pathological mutations are also shown (van der Kamp & Daggett, 2009). Bottom. Model based on 1QLZ for the C-terminal part. Cu ions added based on (Walter et al.2007).

Figure 15

Fig. 15. LPMO with histidine brace Cu site. A starch-active lytic polysaccharide monooxygenase (LPMO) from Aspergillus Oryzae (4OPB; (Lo Leggio et al.2015)) with the Cu site enlarged.

Figure 16

Fig. 16. Illustration of how increased Cu supply to macrophages and simultaneous inhibition of bacterial Cu export may be a new dual strategy to combat bacterial infections through Cu toxicity in phagosomes.